Macrophages are central to the biology of tuberculosis (TB). They are among the first host cells to encounter Mycobacterium tuberculosis (Mtb) in the lung, they help determine whether infection is cleared, contained, or progresses, and they remain key architects of granuloma formation, bacterial persistence, immune regulation, tissue remodeling, and treatment response.

Creative Biolabs provides a comprehensive solution set. From high-quality macrophage sourcing and in vitro infection systems to high-content phenotyping, co-culture platforms, granuloma-like models, and efficacy-oriented translational assays, we support TB research programs from discovery through preclinical decision-making.

Role of Macrophages in TB

Infection of a host with Mtb is initiated following the inhalation of droplets (aerosols) containing a small number of bacilli. In the early stage of Mtb infection, macrophages show pro-inflammatory responses like M1 macrophages contributing to the restriction of Mtb survival (Mtb-infected M1 macrophages are transformed into M2 macrophages with suppressive activities in their antibacterial responses over time). Alveolar macrophages can effectively phagocytize and transfer the phagocytosed Mtb to the destructive environment of lysosomes. However, some bacilli can escape from the lysosome and survive within the macrophage. These macrophages harbor the pathogen and transport it to draining lymph nodes. A small granulomatous lesion develops containing the bacteria. Mtb-infected macrophages can differentiate into foamy macrophages by the accumulation of lipid, which are hallmarks of TB lesions. When foamy macrophages leave the original granuloma to promote the dissemination, giving the bacteria access to nearby airways and thus the ability to spread within the lung and elsewhere within the body. Thus, Mtb-infected alveolar. In the case of immunodeficiency, for example, when T cell function is compromised, unrestricted growth and necrosis within macrophages cause dissemination of tubercle bacilli.

Fig.1 Generation of Mtb-infected foamy macrophages during the formation of TB granulomas.^{1, 3}

Our TB-Focused Macrophage Service Portfolio

Understanding macrophages in TB requires models that capture infection biology, lesion complexity, and macrophage plasticity across disease stages. Creative Biolabs offers a robust, end-to-end service portfolio designed to accelerate TB therapeutic development and mechanistic discovery. By integrating human-relevant in vitro systems, advanced phenotyping, functional infection assays, and translational screening workflows, we empower clients to:

• Characterize macrophage subsets involved in early infection, granuloma evolution, and disease progression.
• Quantify host-pathogen interactions in alveolar macrophages and monocyte-derived macrophages.
• Evaluate compounds, biologics, delivery systems, and host-directed therapeutics for macrophage-centered activity.
• Investigate macrophage metabolism, foam cell formation, and inflammatory reprogramming.
• Generate decision-driving datasets for preclinical development and biomarker strategy.

Macrophage Sourcing, Differentiation, and Phenotyping

We provide macrophage populations relevant to TB biology, including donor-diverse primary human monocyte-derived macrophages, alveolar macrophage-oriented systems where appropriate, iPSC-derived macrophages, and myeloid cell line-based screening platforms. Depending on study goals, macrophages can be differentiated and conditioned under homeostatic, inflammatory, tolerogenic, or TB-mimetic microenvironmental conditions.

Our phenotyping workflows can include:

• Surface marker analysis by multicolor flow cytometry
• High-content imaging of morphology and intracellular bacterial burden
• Transcriptional profiling of inflammatory, antimicrobial, and lipid-handling programs
• Cytokine and chemokine multiplex analysis
• Metabolic profiling, including glycolytic and mitochondrial readouts
• Foam cell induction and lipid droplet quantification
• Phagocytosis, uptake, trafficking, and intracellular survival assays

Macrophage–Mtb Interaction Assays

A core component of our TB offering is the controlled analysis of macrophage–pathogen interaction biology. We support assay design for studying host cell uptake, intracellular persistence, inflammatory signaling, lysosomal trafficking, and cell death phenotypes under defined conditions.

Potential study modules include:

• Mtb or surrogate mycobacterial uptake assays
• Intracellular survival and replication measurement
• Phagosome maturation and lysosomal fusion analysis
• Reactive response profiling and antimicrobial pathway assessment
• Autophagy-associated biomarker analysis
• Cell death phenotyping, including apoptosis-like, necrotic, and mixed injury signatures
• Longitudinal imaging of infected macrophage behavior

Macrophage–T Cell Crosstalk and Immune Coordination

Macrophages do not act alone in TB. They shape, and are shaped by, CD4 T cells, CD8 T cells, regulatory populations, and innate immune partners. Their antigen presentation capacity, cytokine secretion patterns, and costimulatory state affect whether adaptive immunity is productive, exhausted, dysregulated, or tissue-damaging.

We provide crosstalk assays to interrogate:

• Macrophage-driven T cell activation
• Cytokine-dependent skewing of immune responses
• Antigen presentation competence
• Contact-dependent versus secretome-mediated interaction
• Effects of therapeutic agents on macrophage–lymphocyte coordination

Host-Directed Therapeutic Screening

TB drug development increasingly includes host-directed strategies that seek to modulate macrophage behavior alongside direct antimicrobial therapy. Creative Biolabs supports screening and mechanistic evaluation of host-directed candidates across a wide range of modalities.

• Small molecules targeting inflammatory signaling
• Metabolic modulators
• Lipid pathway regulators
• Autophagy-related interventions
• Nanoparticle or liposome delivery systems
• RNA-based payloads
• Cytokine or biologic reprogramming strategies
• Macrophage-targeted formulations
• Combination studies with standard TB therapeutics

Our Integrated Platforms & Assays

Therapies Targeting Macrophages in TB

• Reprogramming macrophages. The Mtb-induced transformation processes from M1 to M2 macrophages are potential immunological targets of TB. Reprogramming macrophages from M2 toward M1 seem to be an approach to inhibit Mtb.
• Upregulation of the production of antimicrobial peptides in Mtb infected macrophages by phenylbutyrate and Vitamin D. Vitamin D inhibits the proliferation of Mtb inside the macrophages through stimulation of the innate immune responses during the infection.
• Targeting Mtb-infected foamy macrophages. A recent study indicated that Mtb-infected foamy macrophages could uptake more fluoroquinolones compared to non-foamy macrophages in vivo, suggesting that it is important to consider the functions of foamy macrophages for anti-TB drug treatment.
• Activation of autophagy in Mtb infected macrophages by rapamycin, metformin, or statin. Activated macrophages are capable to kill Mtb, involving autophagy. For example, rapamycin inhibits mTOR kinase activity, which in turn activates autophagy.
• Increasing anti-inflammatory responses and suppressing pro-inflammatory responses can reduce inflammation and tissue damage. Pro-inflammatory cytokines such as interferon γ (IFNγ), IL-1b, and TNF-a are known to activate autophagy, whereas anti-inflammatory cytokines IL-4, IL-10, and IL-13 seem to inhibit autophagy.

Fig.2 Host-directed therapy (HDT) against Mycobacterium tuberculosis.^{2, 3}

Macrophages are an integral component of pathogenesis and immunity in many diseases. Based on a powerful Macrophage Therapeutics Development Platform, Creative Biolab provides a series of biotechnological services for macrophage development projects to meet our clients' various requirements. Our outstanding scientists can provide customized solutions to address your difficulties.

Related Products

Below are examples of product categories frequently relevant to TB macrophage studies:

Scientific Resources

Q & A

Q: Which macrophage source should I use for TB studies?

A: The best choice depends on your study objective. Primary human macrophages offer strong translational relevance and donor-specific biology. iPSC-derived macrophages offer batch consistency and are useful for genetically controlled studies. Cell lines are often appropriate for high-throughput pilot screens. For many programs, a staged workflow using a screening model followed by validation in primary human macrophages is the most efficient approach.

Q: Can you build models relevant to early lung infection as well as chronic granuloma-like disease?

A: Yes. We can design studies around early alveolar macrophage-oriented infection biology, inflammatory monocyte-derived macrophage responses, or more advanced 3D/granuloma-like systems that model chronic lesion features such as hypoxia, lipid remodeling, and multicellular crosstalk.

Q: How do you evaluate whether a candidate improves macrophage control of TB?

A: We typically use a multidimensional strategy that may include intracellular burden measurements, macrophage viability, inflammatory secretome analysis, trafficking and phagosome-associated readouts, metabolic profiling, and phenotype-specific marker panels. This helps distinguish true host-beneficial activity from nonspecific immune activation.

Q: Do you support host-directed therapeutic programs in addition to standard antimicrobial screening?

A: Yes. We support programs focused on macrophage reprogramming, metabolic modulation, foam cell biology, targeted delivery systems, cytokine pathway intervention, and combination studies with anti-TB agents.

Q: How do I initiate a project or obtain a quote?

A: Simply contact our scientific team with a brief description of your target, modality, TB research question, desired model system, and preferred endpoints. We will then propose a customized study design and provide a detailed quotation.

Creative Biolabs provides the translational macrophage toolset you need for TB discovery and development—from controlled macrophage infection assays to granuloma-relevant models, high-parameter phenotyping, and host-directed therapeutic screening. Tell us about your target, disease stage, and modality, and our scientists will propose a customized TB macrophage research plan built around your program goals.

References

1. Shim, Dahee, Hagyu Kim, and Sung Jae Shin. "Mycobacterium tuberculosis infection-driven foamy macrophages and their implications in tuberculosis control as targets for host-directed therapy." Frontiers in immunology 11 (2020): 910. https://doi.org/10.3389/fimmu.2020.00910
2. Ahmed, Sultan, et al. "Host-directed therapy as a novel treatment strategy to overcome tuberculosis: targeting immune modulation." Antibiotics 9.1 (2020): 21. https://doi.org/10.3390/antibiotics9010021
3. Distributed under Open Access license CC BY 4.0, without modification.